Lancet Infectious Diseases

Papers
(The TQCC of Lancet Infectious Diseases is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
An interactive web-based dashboard to track COVID-19 in real time7682
Estimates of the severity of coronavirus disease 2019: a model-based analysis2654
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study2434
Early dynamics of transmission and control of COVID-19: a mathematical modelling study1702
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study1255
Viral dynamics in mild and severe cases of COVID-191225
A minimal common outcome measure set for COVID-19 clinical research1123
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial1040
A clinical case definition of post-COVID-19 condition by a Delphi consensus1017
Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study932
Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics918
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial879
Clinical and virological data of the first cases of COVID-19 in Europe: a case series868
Real estimates of mortality following COVID-19 infection849
Global impact of the first year of COVID-19 vaccination: a mathematical modelling study835
Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study810
Clinical features and management of human monkeypox: a retrospective observational study in the UK726
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study711
Scientific and ethical basis for social-distancing interventions against COVID-19641
Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study639
Can we contain the COVID-19 outbreak with the same measures as for SARS?631
Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study618
The value of antimicrobial peptides in the age of resistance599
Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study561
COVID-19 and multisystem inflammatory syndrome in children and adolescents558
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study557
Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance550
Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study544
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study544
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study520
Genomic evidence for reinfection with SARS-CoV-2: a case study514
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study469
Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study456
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2454
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study424
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, mult416
A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation410
COVID-19 and medical education407
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical 397
Stigma during the COVID-19 pandemic373
Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series352
The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries347
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study347
The many estimates of the COVID-19 case fatality rate340
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study338
Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study333
Risk of COVID-19 in health-care workers in Denmark: an observational cohort study329
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 328
Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis302
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison301
Exaggerated risk of transmission of COVID-19 by fomites300
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial298
The COVID-19 infodemic293
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study283
Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression266
Pooling of samples for testing for SARS-CoV-2 in asymptomatic people247
Serology testing in the COVID-19 pandemic response246
Smell and taste dysfunction in patients with COVID-19242
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial241
Long-term consequences of COVID-19: research needs235
SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England234
Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study233
Scaling up COVID-19 rapid antigen tests: promises and challenges232
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised230
Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data230
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial228
Taking the right measures to control COVID-19227
Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT223
Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study220
Covert COVID-19 and false-positive dengue serology in Singapore220
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial216
Changes in colistin resistance and mcr-1 abundance in Escherichia coli of animal and human origins following the ban of colistin-positive additives in China: an epidemiological comparative study215
Willingness to vaccinate against COVID-19 in Australia214
SARS-CoV-2: virus dynamics and host response210
Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-cont208
Connecting clusters of COVID-19: an epidemiological and serological investigation206
COVID-19 in Latin America204
COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study200
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical tri198
Open access epidemiological data from the COVID-19 outbreak192
Intention to vaccinate against COVID-19 in Australia191
Monitoring approaches for health-care workers during the COVID-19 pandemic190
The indirect impact of COVID-19 on women187
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study187
COVID-19 in children: the link in the transmission chain186
Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study185
The global incidence and diagnosis of fungal keratitis184
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden184
Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis182
Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis181
Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design181
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis178
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study177
The important role of serology for COVID-19 control175
Likelihood of survival of coronavirus disease 2019174
Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial171
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study171
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial170
Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and 167
What reinfections mean for COVID-19166
Global shortage of personal protective equipment164
SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study162
Baricitinib for COVID-19: a suitable treatment?161
ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5159
SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity159
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis158
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard158
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19156
Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis155
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding154
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wav154
Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study152
Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study150
Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study148
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape146
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis145
Guidelines for pregnant women with suspected SARS-CoV-2 infection141
Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis140
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial140
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies137
Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial132
Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study132
China's successful control of COVID-19131
Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study130
COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England130
Monkeypox outbreaks outside endemic regions: scientific and social priorities129
Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review129
Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US127
Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial126
Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study125
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study124
SARS-CoV-2 and the human-animal interface: outbreaks on mink farms123
Monoclonal antibody therapies against SARS-CoV-2123
COVID-19 disrupts vaccine delivery123
Concerns and motivations about COVID-19 vaccination122
Bell's palsy and SARS-CoV-2 vaccines122
Prevention of monkeypox with vaccines: a rapid review120
Hospitalisation among vaccine breakthrough COVID-19 infections119
Rural areas at risk during COVID-19 pandemic119
Low risk of SARS-CoV-2 transmission by fomites in real-life conditions117
Estimating case fatality rates of COVID-19115
Estimation of COVID-19 outbreak size in Italy115
Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2115
Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled114
Protective immunity after recovery from SARS-CoV-2 infection113
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial113
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB113
Vaccinology: time to change the paradigm?112
SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study110
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study110
Omicron sublineage BQ.1.1 resistance to monoclonal antibodies110
Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective obse109
RT-PCR for SARS-CoV-2: quantitative versus qualitative108
Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2106
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study106
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial104
The urgent need for metallo-β-lactamase inhibitors: an unattended global threat103
Tracking the 2022 monkeypox outbreak with epidemiological data in real-time103
The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation102
Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe99
Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant99
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (CO97
A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China97
Global guideline for the diagnosis and management of the endemic mycoses: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and An97
ChatGPT and antimicrobial advice: the end of the consulting infection doctor?97
New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial97
Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study96
Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland95
Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis95
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study95
Disease X: accelerating the development of medical countermeasures for the next pandemic95
Understanding COVID-19: what does viral RNA load really mean?94
Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study93
SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series93
Genomic-informed pathogen surveillance in Africa: opportunities and challenges93
Appropriateness of antibiotic prescriptions in ambulatory care in China: a nationwide descriptive database study92
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial92
Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review92
BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial92
Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study92
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study90
100 years of Mycobacterium bovis bacille Calmette-Guérin90
The place for remdesivir in COVID-19 treatment88
The world's largest COVID-19 vaccination campaign88
Exhaled Mycobacterium tuberculosis output and detection of subclinical disease by face-mask sampling: prospective observational studies87
PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study87
Global burden and trends of sexually transmitted infections from 1990 to 2019: an observational trend study87
Long COVID in the skin: a registry analysis of COVID-19 dermatological duration86
COVID-19 human challenge studies: ethical issues84
Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.583
Lung fibrosis: an undervalued finding in COVID-19 pathological series83
Epidemic preparedness in urban settings: new challenges and opportunities83
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial82
Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM82
Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis81
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study81
Defining persistent Staphylococcus aureus bacteraemia: secondary analysis of a prospective cohort study81
Hand hygiene in health care: 20 years of ongoing advances and perspectives80
SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients79
First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 202079
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial78
Hydroxychloroquine prophylaxis for COVID-19 contacts in India78
Management of pregnant women infected with COVID-1978
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.377
Complications and mortality of non-typhoidal salmonella invasive disease: a global systematic review and meta-analysis77
Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant76
The importance of understanding the infectious microenvironment76
Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant76
The intersection of COVID-19 and mental health76
Viral loads in clinical samples of men with monkeypox virus infection: a French case series75
Chloroquine or hydroxychloroquine for prophylaxis of COVID-1974
Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy s74
The scientific and ethical feasibility of immunity passports74
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study73
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation 72
Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial71
Hospital-treated infectious diseases and the risk of dementia: a large, multicohort, observational study with a replication cohort71
Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study70
Cavitary tuberculosis: the gateway of disease transmission70
Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study70
Review of 2022 WHO guidelines on the control and elimination of schistosomiasis70
Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis69
Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controll68
Age–sex differences in the global burden of lower respiratory infections and risk factors, 1990–2019: results from the Global Burden of Disease Study 201968
Interferon-γ release assays or tuberculin skin test for detection and management of latent tuberculosis infection: a systematic review and meta-analysis68
Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective 68
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study67
The state of vaccine safety science: systematic reviews of the evidence67
Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study67
Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac67
Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis67
Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study66
Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.8665
Case isolation, contact tracing, and physical distancing are pillars of COVID-19 pandemic control, not optional choices65
Gaps in India's preparedness for COVID-19 control65
COVID-19 vaccine equity and booster doses64
Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccinati64
CoronaVac induces lower neutralising activity against variants of concern than natural infection63
Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark63
SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–2163
Antibiotic prescribing in general practice during COVID-1962
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study62
Global increases in antibiotic consumption: a concerning trend for WHO targets62
Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak62
Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study61
Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study61
Quantifying the global number of tuberculosis survivors: a modelling study61
The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned61
Persistence of IgG response to SARS-CoV-261
Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants61
0.06951904296875